Fig. 6: Effects of pharmacological IGFBP2 signaling blockade on neuronal Ca²⁺ signals.

Stimulus-evoked neuronal Ca²⁺ signals in AstroP2Y1OE or control mice, measured using jGCaMP8s. The Schaffer collaterals were stimulated 300 times with 40 Hz at 0.06 mA. A Linsitinib (10 μM), an IGF-1R antagonist, was treated for 1 h at room temperature. Linsitinib significantly reduced neuronal Ca²⁺ signal in AstroP2Y1OE slices. ACSF, n = 51 ROIs from 4 slices, 3 mice; Linsitinib, n = 52 ROIs from 4 slices, 3 mice (two-sided Mann–Whitney U test). Data are presented as mean ± s.d. B Linstinib did not affect neuronal Ca²⁺ signals in control slices. ACSF, n = 53 ROIs from 6 slices, 4 mice; Linstinib, n = 71 ROIs from 6 slices, 4 mice (two-sided Mann–Whitney U test). Data are presented as mean ± s.d. C IGF-2R antibody (5 μg/mL) was treated for 2 h at room temperature. IgG was used as a control. IgG control, n = 50 ROIs from 5 slices, 3 mice; IGF-2R antibody, n = 50 ROIs from 5 slices, 3 mice (two-sided Mann–Whitney U test). Data are presented as mean ± s.d. D NBI 31772 (10 μM), which blocks IGFBP binding to IGF-1, was treated for 1 h at room temperature. ACSF, n = 35 ROIs from 5 slices, 4 mice; NBI 31772, n = 52 ROIs from 6 slices, 4 mice (two-sided Mann–Whitney U test). Data are presented as mean ± s.d. Source data are provided as a Source Data file.